Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBT (2020 - 2025)

Mirum Pharmaceuticals has reported EBT over the past 6 years, most recently at -$5.0 million for Q4 2025.

  • Quarterly results put EBT at -$5.0 million for Q4 2025, up 79.63% from a year ago — trailing twelve months through Dec 2025 was -$21.4 million (up 75.35% YoY), and the annual figure for FY2025 was -$21.4 million, up 75.35%.
  • EBT for Q4 2025 was -$5.0 million at Mirum Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Over the last five years, EBT for MIRM hit a ceiling of $57.3 million in Q4 2021 and a floor of -$73.7 million in Q2 2023.
  • Median EBT over the past 5 years was -$27.3 million (2023), compared with a mean of -$24.9 million.
  • Biggest five-year swings in EBT: surged 254.01% in 2021 and later plummeted 163.34% in 2022.
  • Mirum Pharmaceuticals' EBT stood at $57.3 million in 2021, then plummeted by 163.34% to -$36.3 million in 2022, then grew by 2.36% to -$35.4 million in 2023, then skyrocketed by 31.24% to -$24.4 million in 2024, then soared by 79.63% to -$5.0 million in 2025.
  • The last three reported values for EBT were -$5.0 million (Q4 2025), $2.6 million (Q3 2025), and -$5.5 million (Q2 2025) per Business Quant data.